


Our Locations



Contact

Gerresheimer AG
 Klaus-Bungert-Strasse 4 · 40468 Duesseldorf · Germany
 Phone +49 211 6181-00
 Fax +49 211 6181-295
 E-mail info@gerresheimer.com

Group Communication & Marketing
 Phone +49 211 6181-250
 Fax +49 211 6181-241
 E-mail j.kuerten@gerresheimer.com

Investor Relations
 Phone +49 211 6181-257
 Fax +49 211 6181-121
 E-mail gerresheimer.ir@gerresheimer.com

www.gerresheimer.com



Gerresheimer Shares

Share reference data

ISIN	DE000A0LD6E6
WKN	A0LD6E
Kürzel Bloomberg	GXI
Kürzel Reuters	GXIG.DE
Stock index membership	MDAX, CDAX, HDAX, Prime All Share, Classic All Share, EURO STOXX TMI and further sector and size indexes
Listings	Berlin, Duesseldorf, Frankfurt (Xetra & floor trading), Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

Shareholder structure by region

Top 25 Investors


United Kingdom 16 %

Germany 8 %

Other 22 %

Netherlands 22 %

North America 32 %



Gerresheimer shares: key data

	2017	2016
Number of shares at reporting date in million	31.4	31.4
Share price ¹⁾ at reporting date in EUR	67.06	68.85
Market capitalization at reporting date in EUR m	2,105.7	2,161.9
Share price high ¹⁾ during reporting period in EUR	78.01	76.86
Share price low ¹⁾ during reporting period in EUR	61.03	57.10
Earnings per share in EUR	3.21	3.87
Dividend per share in EUR	1.10 ²⁾	1.05

¹⁾ Xetra closing price.

²⁾ Proposed appropriation of net earnings.

Vision – Mission – Values



Our Vision

Gerresheimer will become the leading global partner for enabling solutions that improve health and well-being.

Our success is driven by the passion of our people.

Our Mission

We will achieve our vision by:

- understanding our customers and providing them with solutions to both their present and future needs
- living our commitment to excellent quality and continuous innovation
- leveraging our competence and technological leadership by acting as one global team
- becoming a preferred employer with highly motivated and passionate employees all over the world and, in so doing, by
- expanding our global reach and creating profitable and sustainable growth

Our Values

Integrity Innovation
 Excellence Teamwork
 Responsibility

Corporate Responsibility

Principles

Corporate responsibility is firmly anchored in our vision, mission and our values. We act in accordance with these principles at all our worldwide sites, and we take a holistic approach to sustainability. In addition to social and economic sustainability, we are particularly committed to the protection of the environment.


Environmental policy

At Gerresheimer, environmental protection goes hand in hand with the efficient use of energy. We optimize energy usage by regularly overhauling and renewing our energy-intensive equipment such as the furnaces at our molded glass facilities.

The goals, strategies and success of our environmental initiatives and actions are regularly published as a result of our participation in the Carbon Disclosure Project (CDP). The goal of our environment strategy is to decrease the emissions to revenue ratio.

www.gerresheimer.com/en/company/corporate-responsibility.html

Clear improvement in CO₂ emissions relative to revenues (t/EUR k)



¹⁾ Excluding the Life Science Research Division (sold as of October 31, 2016).

Working at Gerresheimer



Achievement and Passion

As a global leader in our sector, we are always looking for employees with diverse specializations and skill sets. We aren't just seeking motivated young specialists and managers, but also experienced personnel.

We offer:

- An interesting work environment in a growing international market
- An open and appreciative corporate culture
- Interesting roles and committed colleagues
- Competence and a tradition of over 150 years

Options for young professionals

We offer diverse entry opportunities:

- Individual trainee programs
- Combined apprenticeship and degree programs
- Apprenticeships in more than 15 different professions
- Internships



Short Profile

Overview

Gerresheimer is a leading global partner

... to the pharma and healthcare industry. With our specialty glass and plastic products, we contribute to health and well-being. We have worldwide operations and about 10,000 employees manufacture our products in local markets, close to our customers. With our plants in Europe, North America, South America and Asia, we generate revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging and products for the safe, simple administration of medicines: Insulin pens, inhalers, micro pumps, prefillable syringes, injection vials, ampoules, bottles and containers for liquid and solid medicines with closure and safety systems as well as packaging for the cosmetics industry.

Our Customers

Gerresheimer has developed longstanding relationships with customers of all sizes around the world. Our customer base includes both international and national pharmaceutical companies, American pharmacies as well as companies in the diagnostic and medical technology industries. We also supply numerous cosmetic customers with our products.

Management Board



Dietmar Siemssen	Rainer Beaujean	Dr. Lukas Burkhardt	Andreas Schütte
Chief Executive Officer	Chief Financial Officer	Primary Packaging Glass Division	Plastics & Devices / Advanced Technologies Divisions

Our Divisions



Plastics & Devices

The product portfolio of the Plastics & Devices Division includes complex, customer-specific products for the simple and safe administration of medicines, such as insulin pens, inhalers and prefilled syringes. Also included are diagnostics and medical technology products such as lancets and test systems, as well as pharmaceutical plastic containers for liquid and solid medicines with closure and safety systems.

Primary Packaging Glass

The Primary Packaging Glass Division produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons and cream jars.

Advanced Technologies

With the acquisition of the Swiss technology company Sensile Medical, we have laid the groundwork for our new division, which will be dedicated to developing and producing intelligent drug delivery systems.

We offer systems like these complete with state-of-the-art digital and electronic technologies to pharmaceutical and biotech companies. Our current portfolio encompasses patented micro pumps for self-treating diabetes or heart disease, for example.

Our Products



... are important

and convenient



solutions for everyday life




15.5 billion products annually
500 pieces per second


Gerresheimer in Figures

Revenues by market segment


Consolidated revenues 2017: EUR 1,348.3 Mio.



Revenues by region



Employees by region



Our Innovations

Gx® Elite Glass Vials
2-3 times harder than type-I standard glass



Micro pump for Parkinson's treatment
CE declaration obtained



Gx® RTF Vials powered by Ompi EZ-fill®
Standardized packaging platform for sterile vials



Fits through many mailboxes and is therefore ideal for online suppliers
Duma® Pocket



Metal-free Gx RTF® glass syringe
for sophisticated medications



Gx RTF® ClearJect®
a COP syringe with cannula for sensitive medications



Full solution for irradiated products incl. validation
Irradiated dropper bottles



Gx InnoSafe®
avoids inadvertent needle stick injuries



Group Key Figures

Financial Year end November 30 (IFRS) in EUR million	FY 2017	FY 2016	Change in % ⁴⁾
Revenues organic ¹⁾	1,348.3	1,375.5	-2.0 -1.8
Adjusted EBITDA ²⁾ in % of revenues	310.8 23.1	307.8 22.4	1.0 -
Net income from continuing operations	103.1	104.5	-1.4
Adjusted net income from continuing operations after non-controlling interests ³⁾	127.5	127.8	-0.3
Dividend per share in EUR	1.10 ⁵⁾	1.05	+4.8
Equity ration in %	32.3	32.1	+20 bps
Net financial debt	712.7	788.2	-9.6
Capital expenditure	118.6	113.2	+4.8

¹⁾ Organic: Adjusted for currency effects and acquisitions/divestments.
²⁾ Adjusted EBITDA: Earnings before income taxes, net finance expense, amortization of fair value adjustments, depreciation and amortization, impairment losses, restructuring expenses and one-off income and expenses.
³⁾ Adjusted net income from continuing operations after non-controlling interests: Consolidated net income from continuing operations after non-controlling interests before non-cash amortization of fair value adjustments, restructuring expenses, impairment losses, one-off income and expenses (including significant non-cash expenses), and the related tax effects.
⁴⁾ The change has been calculated on a EUR k basis.
⁵⁾ Proposed appropriation of retained earnings.

